Core Viewpoint - The announcement details a share reduction plan by Shenzhen Jun Tian Investment Enterprise (Limited Partnership), which holds 10,067,751 shares of Chengdu Xian Dao Pharmaceutical Development Co., Ltd., representing 2.51% of the company's total share capital [2][3][4]. Group 1: Shareholder Reduction Plan - Shenzhen Jun Tian plans to reduce its holdings of 10,067,751 shares through centralized bidding and block trading, with the reduction period set from January 22, 2026, to April 21, 2026 [4]. - The shareholder has obtained the necessary approvals and is compliant with relevant regulations regarding the reduction of shares held by venture capital fund shareholders [4][6]. - The reduction will be limited to a maximum of 1% of the total shares through centralized bidding and 2% through block trading within any consecutive 30-day period [4]. Group 2: Shareholder Background - As of the announcement date, Shenzhen Jun Tian holds 10,067,751 shares, which is 2.51% of the total share capital of Chengdu Xian Dao [3]. - The shareholder has made commitments regarding the reduction, including a maximum of 50% of their shares held prior to the public offering can be reduced within two years after the lock-up period [6]. Group 3: Compliance and Regulations - The reduction plan is in accordance with the relevant laws and regulations, including the Securities Law of the People's Republic of China and specific guidelines for venture capital fund shareholders [9]. - The company will adhere to all legal and regulatory requirements during the share reduction process and will fulfill its information disclosure obligations [9].

Shareholder Reductions - RS Technologies and Cangyuan Investment plan to reduce their holdings by no more than 3% in Youyan Silicon [1] - Yuexiu Capital intends to sell no more than 1% of the total share capital of CITIC Securities [1] - Multiple shareholders of Ruimaite plan to collectively reduce their holdings by no more than 4.98% [1] - The controlling shareholder of Brother Technology plans to reduce its holdings by no more than 2% [1] - Jinggangshan Chengxing intends to reduce its holdings in Guanggang Gas by no more than 0.9997% [1] - The controlling shareholder of Lianchuang Optoelectronics, Electronic Group, plans to reduce its holdings by no more than 2% [1] - Shenzhen Jun Tian, a shareholder of Chengdu Xian Dao, plans to reduce its holdings by no more than 2.51% [1] - Shareholder Fan Jun of Xidi Micro plans to reduce no more than 251,230 shares [1] - Shareholder Cheng Gao Century of Decai Co., Ltd. plans to reduce 4.1973 million shares [1] - Hangzhou Xintou and its concerted action party Hangzhou Haoyue have cumulatively reduced 1.29% of shares in Meinian Health [1] - Guotou Chuangye Fund has cumulatively reduced 1.06% of shares in Fuchuang Precision [1] - New Momentum Fund has cumulatively reduced 0.9926% of shares in Shannon Chip Creation [1] - Deputy General Manager Li Zuqing of Guangli Technology plans to reduce no more than 701,600 shares [1] Other Notable Events - Yuan Zhishuang of Dingxin Communications is under investigation by the Securities Regulatory Commission for suspected short-term trading of company shares [1] - Shimao Energy has terminated its plans for a change in control [1]

北京商报讯1月16日晚间，成都先导（688222）发布公告称，公司股东深圳市钧天投资企业（有限合 伙）（以下简称"深圳钧天"）拟通过集中竞价和大宗交易的方式减持其所持有的公司股份合计1006.78 万股，拟减持股份占公司总股本的比例约为2.51%。 公告显示，截至公告披露日，公司股东深圳钧天持有公司股份1006.78万股，占公司总股本的2.51%。这 也意味着，深圳钧天此次减持系清仓式减持。 （文章来源：北京商报） ...

Group 1 - Su Dawei Ge's wholly-owned subsidiary plans to invest in a fund focusing on semiconductor, new energy, AI, and aerospace sectors, contributing 20 million yuan for a 10.2302% stake [2] - Shimao Energy terminates plans for a change in control after failing to reach consensus on key terms, with stock resuming trading on January 19 [3] - Huatian Hotel's controlling shareholder is planning a merger and restructuring, potentially changing the actual controller to the Hunan Provincial State-owned Cultural Assets Supervision and Administration Commission [4] Group 2 - Jinpu Titanium's subsidiary Xuzhou Titanium will cease production due to intensified market competition, which is expected to significantly impact revenue in 2026 [5] - Dingxin Communications' deputy general manager is under investigation by the CSRC for suspected short-term trading of company stock, but it will not affect the company's operations [6] - Xinhang New Materials plans to acquire 51% of Hairete for 12.8826 million yuan to explore new growth points [7] Group 3 - Hualan Co.'s controlling shareholder raises the upper limit of its share buyback plan from 58.08 yuan to 86.66 yuan per share [8] - Wanhua Chemical's MDI Phase II facility has resumed normal production after maintenance [9] - Junsheng Electronics introduces a strategic investor, with a 1 billion yuan investment aimed at reducing overall debt [10] Group 4 - Jiangbolong announces five shareholders plan to transfer 3% of the company's shares through a pricing inquiry [11] - Haitai Technology expects a net profit increase of 226.86% to 323.97% in 2025, driven by high industry demand and increased orders [13] - Northern Rare Earth anticipates a net profit increase of 116.67% to 134.6% in 2025 due to successful market expansion [14] Group 5 - Lanke Technology forecasts a net profit increase of 52.29% to 66.46% in 2025, benefiting from the AI industry trend [15] - Keda expects a net profit increase of 52.21% to 67.43% in 2025, driven by growth in data center and new energy sectors [16] - Cambridge Technology predicts a net profit increase of 51% to 67% in 2025, supported by strong demand in core business areas [17] Group 6 - China Electric Research anticipates a net profit of 533 million yuan in 2025, a 14.04% increase year-on-year [18] - China Automotive Research expects a net profit of 1.06 billion yuan in 2025, a 17.85% increase year-on-year [19] - Zhongcheng Co. forecasts a net profit of 276 million to 414 million yuan in 2025, recovering from a previous loss [20] Group 7 - Junda Co. expects a net loss of 1.2 billion to 1.5 billion yuan in 2025, worsening from a previous loss of 591 million yuan [21] - Guangdian Network anticipates a net loss of 1.29 billion to 1.55 billion yuan in 2025, attributed to declining traditional business revenue [22] - Jiugang Hongxing predicts a net loss of approximately 1.879 billion yuan in 2025, an improvement from a previous loss of 2.617 billion yuan [23] Group 8 - Jinbo Co. expects a net loss of around 1.4 billion yuan in 2025, worsening from a previous loss of 815 million yuan [24] - Dongjiang Environmental anticipates a net loss of 1.05 billion to 1.35 billion yuan in 2025, due to ongoing industry adjustments [25] - Daqing Energy forecasts a net loss of 1 billion to 1.3 billion yuan in 2025, despite improvements in production costs [26] Group 9 - Dongzhu Ecology expects a net loss of 935 million to 1.135 billion yuan in 2025, impacted by macroeconomic factors [27] - Weiyuan Co. anticipates a net loss of 950 million to 1.05 billion yuan in 2025, turning from profit to loss [28] - Huanghe Xuanfeng predicts a net loss of 850 million yuan in 2025, an improvement from a previous loss of 983 million yuan [29] Group 10 - Fushun Special Steel expects a net loss of 770 million to 870 million yuan in 2025, turning from profit to loss [30] - China First Heavy Industries anticipates a net loss of 310 million to 460 million yuan in 2025, significantly reducing losses compared to the previous year [31] - Jishi Media forecasts a net loss of 364 million to 455 million yuan in 2025, with overall revenue expected to remain stable [33] Group 11 - Guangxi Energy expects a net loss of 170 million to 220 million yuan in 2025, turning from profit to loss [34] - Baike Bio anticipates a net loss of 220 million to 280 million yuan in 2025, turning from profit to loss due to declining vaccine sales [35] - Zhongtai Auto expects to remain in a loss position for 2025, with a projected positive net asset value by year-end [36] Group 12 - Nasda anticipates a loss for 2025 due to significant asset sales and industry policy adjustments [37] - Rongsheng Development expects to report a loss for 2025, with the amount not exceeding the previous year's audited net assets [38] Group 13 - China National Materials signs a contract worth 299 million Canadian dollars for engineering services in Canada [40] - Dayu Water-saving's subsidiary wins a project worth 133 million yuan for water source guarantee engineering [41] - Hailu Heavy Industry reports new orders totaling 1.941 billion yuan for 2025 [42]

Core Viewpoint - Chengdu Xian Dao Pharmaceutical Development Co., Ltd. announced that shareholder Shenzhen Jun Tian Investment Enterprise (Limited Partnership) plans to reduce its stake by 10,067,751 shares, accounting for 2.51% of the total share capital, within three months through centralized bidding and block trading [1][3]. Shareholder and Holding Situation - As of the announcement date, Shenzhen Jun Tian holds 10,067,751 shares, representing 2.51% of the company, acquired before the IPO. It is not a controlling shareholder or a significant stakeholder [2]. - Jun Tian's action partner, Jun Tian Venture Capital Co., Ltd., holds 0 shares, maintaining the combined holding at 2.51% [2]. Details of the Reduction Plan - The reduction will occur from January 22, 2026, to April 21, 2026, with a total of 10,067,751 shares to be sold [3]. - Shenzhen Jun Tian has received approval from the China Securities Investment Fund Industry Association and complies with relevant regulations regarding the reduction of shares [3]. - The reduction must adhere to specific rules, such as not exceeding 2% of the total shares within a 30-day period through block trading [3]. Historical Reduction Situation - In the past 12 months, Shenzhen Jun Tian reduced its holdings by 1,859,413 shares (0.46% of total shares) between August 28, 2025, and November 3, 2025, at prices ranging from 24.01 to 30.05 yuan per share [4].

人民财讯1月16日电，成都先导(688222)1月16日公告，深圳市钧天投资企业(有限合伙)(简称"深圳钧天") 持有公司2.51%股份，拟通过集中竞价和大宗交易的方式，减持公司股份合计不超1006.78万股(占公司 总股本的2.51%)。 ...

证券代码：688222 证券简称：成都先导 公告编号：2026-001 成都先导药物开发股份有限公司 关于股东减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 本次减持计划的股东深圳市钧天投资企业（有限合伙）（以下简称"深圳钧天"） 有关于减持意向的承诺： （1）减持方式：减持成都先导药物开发股份有限公司（以下简称"公司"、"发行 人"）股份应符合相关法律、法规、规章的规定，具体方式包括但不限于交易所 集中竞价交易方式、大宗交易方式、协议转让方式等； （2）减持价格：所持股票在锁定期满两年后减持的，减持价格符合相关法律法 规规定。 本次减持股东的持股基本情况 截至本公告披露日，公司股东深圳钧天持有公司股份 10,067,751 股，占公司 总股本的 2.51%。 减持计划的主要内容 深圳钧天拟通过集中竞价和大宗交易的方式减持其所持有的公司股份合计 10,067,751 股，拟减持股份占公司总股本的比例约为 2.51%，自减持计划发布之 日起 3 个交易日之后的 3 个月内（202 ...

成都先导公告，深圳钧天拟通过集中竞价和大宗交易的方式减持其所持有的公司股份合计10,067,751 股，拟减持股份占公司总股本的比例约为2.51%，自减持计划发布之日起3个交易日之后的3个月内 （2026年1月22日至2026年4月21日）实施。截至本公告披露日，公司股东深圳钧天持有公司股份 10,067,751股，占公司总股本的2.51%。 ...

Core Viewpoint - Chengdu XianDao announced that its shareholder Shenzhen JunTian Investment Enterprise (Limited Partnership) plans to reduce its holdings by up to 10.0678 million shares, representing no more than 2.51% of the total share capital, due to financial needs and arrangements [1] Group 1 - The reduction period is set from January 22, 2026, to April 21, 2026 [1] - The shares to be reduced were acquired prior to the IPO [1] - Shenzhen JunTian has committed that the reduction plan complies with relevant laws and regulations and previous commitments, with no circumstances preventing the reduction [1] Group 2 - The share reduction is not expected to have a significant impact on the company's governance and ongoing operations [1]

Group 1 - Chengdu Xian Dao Pharmaceutical Development Co., Ltd. experienced a decline of 5.19% in stock price, reaching 35.46 CNY per share, with a trading volume of 607 million CNY and a turnover rate of 4.17%, resulting in a total market capitalization of 14.208 billion CNY [1] - The company, established on February 22, 2012, and listed on April 16, 2020, specializes in early-stage drug discovery services using its core DEL technology, with 99.97% of its revenue coming from new drug research services [1] - The revenue breakdown includes customized services at 59.92%, full-time equivalent services at 27.20%, and other services at 12.84%, with a negligible 0.03% from supplementary sources [1] Group 2 - According to data from the top ten holdings of funds, Wan Jia Fund has one fund heavily invested in Chengdu Xian Dao, specifically the Wan Jia Quantitative Tongshun A (005650), which held 30,200 shares, accounting for 1.91% of the fund's net value, ranking as the tenth largest holding [2] - The estimated floating loss for the fund today is approximately 58,600 CNY [2] - Wan Jia Quantitative Tongshun A was established on May 4, 2018, with a latest scale of 29.9221 million CNY, achieving a year-to-date return of 7.53% and a one-year return of 37.32% [2]